Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 1/20 | 0.61 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | MLYCD | O95822 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | NAMPT | P43490 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.52 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.52 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | BRD4 | O60885 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5505094 | 0.86 | NAMPT (0.58) | CACNA1BAPBA1SMN1; SMN2HTTNAMPT | |
| SCHEMBL23786313 | 0.86 | NPC1 (0.55) | CACNA1BAPBA1SMN1; SMN2HTTMLYCD | |
| SCHEMBL18893317 | 0.85 | MLYCD (0.58) | SMN1; SMN2HTTMLYCDHSD17B10NAMPT | |
| SCHEMBL8590217 | 0.84 | MLYCD (0.70) | SMN1; SMN2HTTMLYCDNAMPTALDH1A1 | |
| SCHEMBL20086461 | 0.84 | ALDH1A1 (0.60) | SMN1; SMN2HTTMLYCDHSD17B10NAMPT | |
| SCHEMBL17633861 | 0.83 | CACNA1B (0.54) | CACNA1BAPBA1SMN1; SMN2HTTPKM | |
| SCHEMBL13116021 | 0.83 | ALDH1A1 (0.60) | CACNA1BAPBA1SMN1; SMN2HTTPKM | |
| SCHEMBL5694517 | 0.82 | NPC1 (0.71) | CACNA1BAPBA1SMN1; SMN2HTTALDH1A1 | |
| SCHEMBL13210697 | 0.82 | CACNA1B (0.85) | CACNA1BAPBA1SMN1; SMN2HTTPKM | |
| SCHEMBL13761376 | 0.81 | MLYCD (0.58) | SMN1; SMN2HTTMLYCDNAMPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1332363-A4 | DETECTION OF NEURODEGENERATIVE DISORDERS | DOUBLE KAY (AU) | 2007-08-29 | — | — | EP | claimed |
| US-7005546-B2 | Acetamidobenzamide compounds for neurodegenerative disorders | RENOVIS, INC. (US) | 2006-02-28 | — | — | US | claimed |
| US-20050260577-A1 | Detection of neurodegenerative disorders | POWMRI LIMITED (AU) | 2005-11-24 | — | — | US | claimed |
| US-20040266881-A1 | Acetamidobenzamide compounds for neurodegenerative disorders | RENOVIS, INC. | 2004-12-30 | — | — | US | claimed |
| US-20040167226-A1 | Methods for the treatment of pain and traumatic injury using benzamides and compositions containing the same | RENOVIS, INC. | 2004-08-26 | — | — | US | claimed |
| US-6759433-B2 | FOR THERAPY OF PARKINSON'S DISEASE | RENOVIS, INC. | 2004-07-06 | — | — | US | claimed |
| US-20030176510-A1 | Acetamidobenzamide compounds for neurodegenerative disorders | RENOVIS, INC. | 2003-09-18 | — | — | US | claimed |
| EP-1332363-A1 | DETECTION OF NEURODEGENERATIVE DISORDERS | UNISEARCH LIMITED (AU) | 2003-08-06 | — | — | EP | claimed |
| US-6509378-B2 | Parkinson's disease; ability to antagonize MPTP induced reduction in dopamine levels; amidation of the nitrobenzoyl halide with alkylamine | CENTAUR PHARMACEUTICALS, INC. | 2003-01-21 | — | — | US | claimed |
| WO-2002031499-A1 | DETECTION OF NEURODEGENERATIVE DISORDERS | UNISEARCH LIMITED (AU) | 2002-04-18 | — | — | WO | claimed |
| US-20010037040-A1 | Acetamidobenzamide compounds for neurodegenerative disorders | RENOVIS, INC. | 2001-11-01 | — | — | US | claimed |
| EP-0819113-B1 | BENZAMIDES FOR NEURODEGENERATIVE DISORDER TREATMENT | CENTAUR PHARMACEUTICALS INC (US) | 2001-06-27 | — | — | EP | claimed |
| US-6194465-B1 | ADMINISTERING ACETAMIDO-, NITRO-, OR AMINO-MONO- OR DISUBSTITUTED N-ALKYL BENZAMIDE COMPOUNDS SUCH AS N-TERT-BUTYL-4-ACETAMIDOBENZAMIDE FOR PROPHLAXIS OR TREATMENT OF AN INFLAMMATORY BOWEL CONDITION IN A PATIENT | CENTAUR PHARMACEUTICALS, INC. | 2001-02-27 | — | — | US | claimed |
| US-5955506-A | ACETAMIDOBENZAMIDE COMPOUNDS FOR TREATMENT OF PARKINSON'S DISEASE | CENTAUR PHARMACEUTICALS, INC. (US) | 1999-09-21 | — | — | US | claimed |
| US-10398783-B2 | Antiproliferative compounds and conjugates made therefrom | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180110873-A1 | ANTIPROLIFERATIVE COMPOUNDS AND CONJUGATES MADE THEREFROM | BRISTOL-MYERS SQUIBB COMPANY | 2018-04-26 | — | — | US | disclosed |
| US-8003662-B2 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-5659082-A | Nitro- and aminobenzamide compounds for neurodegenerative disorders | CENTAUR PHARMACEUTICALS, INC. (US) | 1997-08-19 | — | — | US | disclosed |
| US-5658953-A | Pharmaceutical compositions of acetamidobenzamide compounds for neurodegenerative disorders | CENTAUR PHARMACEUTICALS, INC. (US) | 1997-08-19 | — | — | US | disclosed |
| US-5643965-A | TREATMENT OF DOPAMINE ASSOCIATED NERVOUS SYSTEM DISORDERS | CENTAUR PHARMACEUTICALS, INC. (US) | 1997-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266881-A1 | Acetamidobenzamide compounds for neurodegenerative disorders | SNCA, PARK7, GBA1 | CACNA1B 1087/4885APBA1 29/4885SMN1; SMN2 8/4885 |
| US-20010037040-A1 | Acetamidobenzamide compounds for neurodegenerative disorders | SNCA, PARK7, GBA1 | CACNA1B 1087/4885APBA1 29/4885SMN1; SMN2 8/4885 |
| US-20040167226-A1 | Methods for the treatment of pain and traumatic injury using benzamides and compositions containing the same | CNR1, NAA50, CNR2 | CACNA1B 191/4885APBA1 529/4885SMN1; SMN2 123/4885 |
| US-20030176510-A1 | Acetamidobenzamide compounds for neurodegenerative disorders | SNCA, PARK7, GBA1 | CACNA1B 1087/4885APBA1 29/4885SMN1; SMN2 8/4885 |
| US-20180110873-A1 | ANTIPROLIFERATIVE COMPOUNDS AND CONJUGATES MADE THEREFROM | MKI67, HDGF, PCLAF | CACNA1B 4789/4885APBA1 4156/4885SMN1; SMN2 2292/4885 |
| US-10398783-B2 | Antiproliferative compounds and conjugates made therefrom | MKI67, HDGF, PCLAF | CACNA1B 4789/4885APBA1 4156/4885SMN1; SMN2 2292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.